Plasma free 3-methpxy-4-hydroxyphenylglycol predicts response to fluoxetine

Biological Psychiatry

Volumn 41, Issue 7, 1997, Pages 774-781

  Ko, Huei Chen ^a,c   Lu, Ru Band ^b   Shiah, I Shin ^b   Hwang, Cheng Chia ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

3 methoxy 4 hydroxyphenylglycol fluoxetine; Depression; Maprotiline; Serotonin; Treatment response

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BROMAZEPAM; FLUOXETINE; MAPROTILINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PLATELETS; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; HUMANS; MALE; MAPROTILINE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; PERSONALITY INVENTORY; PROGNOSIS; SEROTONIN; TREATMENT OUTCOME;

EID: 0030946511     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00207-7     Document Type: Article

References (37)

1. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev. Washington, DC: American Psychiatric Press.
2. Berger PA (1977): Antidepressant medications and the treatment of depression. In Barchas JD, Berger PA, Ciaranello RD, Elliott GR (eds), Psychopharmacology, New York: Oxford University Press, pp 174-206.
3. Berger PA, Barchas JD (1977): Biochemical hypotheses of affective disorder. In Barchas JD, Berger PA, Ciaranello RD, Elliott GR (eds), Psychopharmacology. New York: Oxford University Press, pp 151-173.
4. Blombery PA, Kopin IJ, Gordon EK, Markey SP, Ebert MH (1980): Conversion of MHPG to vanillylmandelic acid. Implications for the importance of urinary MHPG. Arch Gen Psychiatry 37:1095-1098.
5. Bowers MB, Swigar ME, Hoffman FJ, Goicoechea N (1988): Characteristics of patients with the highest plasma catecholamine metabolite levels. Am J Psychiatry 145:246-248.
6. Endicott J, Spitzer RC (1978): A diagnostic interview. The schedule for affective disorder and schizophrenia. Arch Gen Psychiatry 35:837-844.
7. Fuller RW, Wong DT (1987): Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol 7(suppl 6):363-433.
8. Garvey M, Hollon SD, DeRubeis RJ, Evans MD, Tuason VB (1990): Does 24-h urinary MHPG predict treatment response to antidepressants? I. A review. J Affect Disord 20:173-179.
9. Hamilton M (1967): Development of a rating scales for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
10. Janicak PG, Davis JM, Chan C, Altman E, Hedeker D (1986): Failure of urinary MHPG levels to predict treatment response in patients with unipolar depression. Am J Psychiatry 143: 1398-1402.
11. Kaplan HI, Sadock BJ, Grelb JA (1994): Synopsis of Psychiatry, 7th ed. Baltimore: Williams and Wilkins, pp 139-140.
12. Kopin IJ, Gordon EK, Jimerson DC, Polinsk RJ (1983): Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 219:73-75.
13. Kopin IJ, Blombery P, Ebert MH, et al (1984a): Disposition and metabolism of MHPG-CD3, in humans: Plasma MHPG as the principal pathway of norepinephrine metabolism and as important determinant of CSF levels of MHPG. Adv Biochem Psychopharmacol 39:57-68.
14. Kopin IJ, Jimerson DC, Markey SP, Ebert MH, Polinsky RJ (1984b): Disposition and metabolism of MHPG in humans: Application to studies in depression. Pharmacopsychiatry 17:3-8.
15. Lu RB, Ko HC, Lin YT, Shen LJ (1991a). Effect of fluoxetine and maprotiline on platelet 5-HT in depressive patients. Biol Psychiatry 29(suppl):135A.
16. Lu RB, Ko HC, Lin YT, Shen LJ (1991b): Platelet 5-HT in depression: A preliminary study. Chin Psychiatry 5:29-35.
17. Maas JW (1975): Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. Arch Gen Psychiatry 32:1357-1361.
18. Maas JW, Fawcett JA, Dekirmenjian H (1972): Catecholamine metabolism, depressive illness, and drug response. Arch Gen Psychiatry 26:252-262.
19. Maas JW, Hattox SE, Greene NM, Landis DH (1979): 3-Methoxy-4- hydroxyphenethyleneglycol production by human brain in vivo. Science 205:1025-1027.
20. Maas JW, Koslow SH, Katz MM, et al (1984): Pre-treatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. Am J Psychiatry 141:1159-1171.
21. Maitre L, Staehelin M, Bein HJ (1971): Blockade of noradrenaline uptake by 34276-Ba, a new antidepressant drug. Biochem Pharmacol 20:2169-2186.
22. Maitre L, Waldmeier PC, Greengrass PM, Jackel J, Sedlucek S, Delini-Stola A (1975): Maprotiline - its position as an anti-depressant in the light of recent neuropharmacological and neurobiochemical findings. J Int Med Res 3(suppl 2):2-15.
23. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L (1989): Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr Scand 79:586-596.
24. Mine K, Okada M, Mishima N, Fujiwara M, Nakagawa T (1993): Plasma-free and sulfoconjugated MHPG in major depressive disorder: Differences between responders to treatment and nonresponders. Biol Psychiatry 34:654-660.
25. Minegishi A, Ishizaki T (1984): Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr A 311:51-57.
26. Molyneux SG, Clarke EE (1985): Precise determination of 5-hydroxytryptamine in platelets and platelet-poor plasma [letter]. Clin Chemistry 31:1573-1574.
27. Montgomery SA, Baldwin D, Shah A, Green M, Fineberg N, Montgomery D (1990): Plasma-level response relationships with fluoxetine and zimelidine. Clin Neuropharmacol 13(suppl 1):S71-S75.
28. Piletz JE, DeMet E, Gwirtsman HE, Halaris A (1994): Disruption of circadian MHPG rhythmicity in major depression. Biol Psychiatry 35:830-842.
29. Pletscher A, Laubscher A (1980): Blood Platelets as models for neurons: Uses and limitations. J Neural Transm Suppl 16:7-16.
30. Potter WZ, Scheinin M, Golden RN, et al (1985): Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites. Arch Gen Psychiatry 42:1171-1177.
31. Richelson E (1988): Synaptic pharmacology of antidepressants. McLean Hosp J 13:67-88.
32. Rosenbaum AH, Schatzberg AF, Maruta T, et al (1980): MHPG as a predictor of antidepressant response to imipramine and maprotiline. Am J Psychiatry 137:1090-1092.
33. Schatzberg AF, Rosenbaum AH, Orsulak PJ, et al (1981). Toward a biochemical classification of depressive disorders: III. Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline. Psychopharmacology 75:34-38.
34. Schildkraut JJ (1973): Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: Preliminary findings. Am J Psychiatry 130:695-699.
35. Stark P, Fuller RW, Wong DT (1985): The Pharmacologic profile of fluoxetine. J Clin Psychiatry 46:7-13.
36. van Praag HM, Kahn RS, Asnis GM, et al (1987): Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders: J Affect Disord 13:1-8.
37. Yazici O, Aricioglu F, Gurvit G, et al (1993). Noradrenergic and serotoninergic depression? J Affect Disord 27:123-129.